What this site is
Clinic Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on Sermorelin (GHRH 1-29 NH2). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The 'clinic' in the domain name is editorial framing — it positions this digest relative to the body of clinical research on sermorelin (the compound), not relative to any clinical service offered by this site. We are a reading room for the published literature, not a prescriber, not a pharmacy, and not a consultation service. Every page is explicit about this distinction.
What we cover
The Sermorelin research record spans three decades: the Geref International Study Group multicenter pediatric GHD trials (1990s–2008), the NIH-supported University of Washington adult aging and cognition studies (Vitiello, Merriam et al.), the JAMA 2004 randomized controlled trial in HIV-associated lipodystrophy (Koutkia, Grinspoon), fundamental pharmacokinetic work (Soule 1994, Kerkhofs 1993), combination secretagogue clinical studies (Sigalos 2017), and the 2024-2025 GHRH receptor and GHRH analog reviews published in Nature Reviews Endocrinology and Reviews in Endocrine & Metabolic Disorders.
We cover mechanism, efficacy data, adverse event profiles, pharmacokinetics, comparison with related GHRH analogs and GH secretagogues, regulatory history, and anti-doping status. We do not cover commercial sources, vendor recommendations, or protocols designed for use outside a research or clinical context.
Regulatory transparency
Sermorelin acetate (Geref) held FDA approval under NDA 020443 for pediatric GH deficiency until 2008, when EMD Serono voluntarily withdrew the product due to manufacturing discontinuation — not safety concerns.[1] No approved brand formulation currently exists in the US. The FDA Pharmacy Compounding Advisory Committee reviewed sermorelin as a nominated bulk drug substance in October 2024.[1]
Sermorelin is classified S2 (Prohibited at all times) on the WADA Prohibited List due to its GH-stimulating activity. It is not a controlled substance in most US state or federal drug schedules, but it requires a prescription.[1]
This site does not sell, prescribe, or recommend sermorelin. All dosing and efficacy data describes published experimental protocols in specific research populations.
Sermorelin acetate (Geref) was voluntarily withdrawn from the US market in 2008 by EMD Serono due to manufacturing discontinuation — not a safety recall. No FDA-approved sermorelin product currently exists in the US. The FDA PCAC reviewed sermorelin as a bulk drug substance nominee in October 2024.
Editorial standards
Every quantitative claim on this site cites a numbered source in the references list. All cited sources are peer-reviewed journal articles, FDA documents, or government clinical trial records. Citations include PubMed IDs, DOIs, and direct URLs wherever available.
No claims are extrapolated beyond what the cited study directly measured. Species, dose, route, population, and study design are identified for every key finding. We report what the literature shows, with the limitations the literature itself acknowledges.
Clinic Sermorelin is an independent editorial project. Not a clinic, not a prescriber, not a vendor. All content is editorial commentary on publicly available peer-reviewed research.